Data · dataset · 2026
Circulating tumour DNA kinetics in recurrent/metastatic head & neck squamous cell sarcinoma (R/M HNSCC) patients
Listed in ZivaHub and Deakin Research Online and DMU Figshare — shown once because both records carry DOI 10.17034/32805257.v1
Immune checkpoint blockade (ICB) has become a standard-of-care in the treatment of recurrent/metastatic head and neck squamous cell cancer (R/M HNSCC).
Description
However, only a subset of patients benefit from treatment and as such there is an urgent need to identify prognostic and predictive biomarkers of response to aid clinical decision-making. This work aims to evaluate clinicopathological features of R/M HNSCC, including markers of systemic inflammation and circulating tumour (ctDNA) kinetics under treatment selection pressure.<br><br>Patients and methods<br>R/M HNSCC patients treated with systemic therapy, platinum-based chemotherapy or ICB, underwent longitudinal blood sampling.
Biomarkers tested included ctDNA, measured by CAncer Personalized Profiling by deep Sequencing (CAPP-Seq) and markers of host inflammation, measured by neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).<br><br>Results<br>Among 53 eligible patients, 16 (30%) received chemotherapy, 30 (57%) ICB [anti-PD1/L1] monotherapy and 7 (13%) combination immunotherapy. Median progression-free (PFS) and overall survival (OS) were 2.8 months (95% CI 1.3-4.3) and 8.2 months (95% CI 5.6-10.8), respectively.
Read the rest (3 more)
Seven (13%) patients experienced a partial response and 21 (40%) derived clinical benefit.<br><br>At baseline, median ctDNA variant allele frequency (VAF) was 4.3%. Baseline ctDNA abundance was not associated with OS (p=0.56) nor PFS (p=0.54). However, a change in ctDNA VAF after one cycle of treatment (ΔVAF (T1-2)) was predictive of both PFS (p<0.01) and OS (p<0.01).
Additionally, decrease in ΔVAF identified patients with longer OS despite early radiological progression, 8.2 vs 4.6 months, HR 0.44 (95% CI 0.19–0.87) p=0.03. At baseline, pre-treatment peripheral blood NLR and PLR are prognostic of PFS and OS. After incorporating NLR and PLR into multivariable Cox models, ctDNA ΔVAF retained an association with OS.<br><br>Conclusions<br>Early dynamic changes in ctDNA abundance, after one cycle of treatment, compared to baseline predicted both OS and PFS in R/M HNSCC patients on systemic therapy.
A decrease in ΔVAF identified patients with longer OS despite early radiological progression. Further prospective studies are needed to validate these findings.<br>
Links
Where it is published
- DOI doi.org/10.17034/32805257.v1 ↗
DOI / persistent id · from zivahub uct ac za
Catalogue records · 1
- OAI-PMH record api.figshare.com/v2/oai?verb=GetRecord&metadataPrefix=oai_dc&identifier=oai%3Af… ↗
metadata API · from zivahub uct ac za
Topics
- From keywords
- Earth & Environmental Science · Earth & Environmental Science · Earth & Environmental Science · Life Sciences · Life Sciences · Life Sciences · Medicine & Health · Medicine & Health · Medicine & Health
- Inferred from text
- Cancer 75% · Immunology 70% · Longitudinal study 65% · Sequencing 75%
Provenance · 3 source records, 17 field assertions
| Source | Key | Last seen | Raw |
|---|---|---|---|
| ZivaHub | oai:figshare.com:article/32805257 | 10 d ago | JSON v1 |
| Deakin Research Online | oai:figshare.com:article/32805257 | 10 d ago | JSON v1 |
| DMU Figshare | oai:figshare.com:article/32805257 | 10 d ago | JSON v1 |
| Field | Assertion | Extractor | Evidence |
|---|---|---|---|
| concepts[disease].local:disease:cancer | enrichment · zivahub uct ac za | keyword-concept-rules@1.0.0 | title+description (75%) |
| concepts[field].anzsrc:group:3204 | enrichment · zivahub uct ac za | taxonomy-embedding@1.1.0 | title+keywords+description (70%) |
| concepts[field].local:field:earth-environmental | mapping · dro deakin edu au | connector:dro_deakin_edu_au@1.0.0 | |
| concepts[field].local:field:earth-environmental | mapping · figshare dmu ac uk | connector:figshare_dmu_ac_uk@1.0.0 | |
| concepts[field].local:field:earth-environmental | mapping · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| concepts[field].local:field:life-sciences | mapping · dro deakin edu au | connector:dro_deakin_edu_au@1.0.0 | |
| concepts[field].local:field:life-sciences | mapping · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| concepts[field].local:field:life-sciences | mapping · figshare dmu ac uk | connector:figshare_dmu_ac_uk@1.0.0 | |
| concepts[field].local:field:medicine-health | mapping · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| concepts[field].local:field:medicine-health | mapping · dro deakin edu au | connector:dro_deakin_edu_au@1.0.0 | |
| concepts[field].local:field:medicine-health | mapping · figshare dmu ac uk | connector:figshare_dmu_ac_uk@1.0.0 | |
| concepts[method].local:method:longitudinal-study | enrichment · zivahub uct ac za | keyword-concept-rules@1.0.0 | title+description (65%) |
| concepts[modality].local:modality:sequencing | enrichment · zivahub uct ac za | keyword-concept-rules@1.0.0 | title+description (75%) |
| description | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | /metadata/dc/description |
| license_text | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| publication_date | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | |
| title | source · zivahub uct ac za | connector:zivahub_uct_ac_za@1.0.0 | /metadata/dc/title |